SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

IOL Chemicals And Pharmaceuticals informs about outcome of board meeting

05 Feb 2022 Evaluate

Pursuant to Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, IOL Chemicals And Pharmaceuticals has informed that the Board of Directors in its meeting held on 4th February 2022 has considered and approved the following: Audited Financial Results for the Quarter and Nine Months ended 31st December 2021. Copy of the said financial results along with unmodified Auditors' Report thereon is enclosed, Declared an Interim Dividend of Rs 4 per Equity Share of Face Value Rs 10 each for the Financial Year 2021-222, Fixed 16th February 2022 as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive the above said Interim Dividend. The payment of the Interim Dividend shall be made to the eligible shareholders before 5th March 2022, Re-appointed Rajender Mohan Malla (00136657) as an Independent Director of the Company, for a second term of 5 years from 6th February 2022 upto 5th February 2027 subject to the requisite approval of the members of the Company and Re-appointed Harpal Singh (06658043) as an Independent Director of the Company, for a second term of 5 years from 6th February 2022 upto 5th February 2027 subject to requisite approval of the members of the Company. The company confirmed and declared that Auditors Report issued by the Statutory Auditors on the financial results of the Company for the quarter and nine months ended 31st December 2021 is an Unmodified Report. The meeting of Board of Directors commenced at 4:00 pm and concluded at 6:18 pm. The above Audited Financial Results are also available on the website of the Company: www.iolcp.com.

The above information is a part of company’s filings submitted to BSE.

IOL Chem & Pharma Share Price

96.51 1.85 (1.95%)
06-May-2026 11:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.80
Dr. Reddys Lab 1285.95
Cipla 1353.55
Zydus Lifesciences 934.35
Lupin 2415.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×